Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
G Li, E De Clercq - Nature reviews Drug discovery, 2020 - nature.com
Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …
you for visiting nature.com. You are using a browser version with limited support for CSS. To …
Type 1 interferons as a potential treatment against COVID-19
Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a
clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the …
clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the …
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 …
PD Monk, RJ Marsden, VJ Tear, J Brookes… - The Lancet …, 2021 - thelancet.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
carries a substantial risk of severe and prolonged illness; treatment options are currently …
carries a substantial risk of severe and prolonged illness; treatment options are currently …
Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)
Background The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting …
the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting …
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a
severe respiratory disease associated with more than 2468 human infections and over 851 …
severe respiratory disease associated with more than 2468 human infections and over 851 …
Compounds with therapeutic potential against novel respiratory 2019 coronavirus
MA Martinez - Antimicrobial agents and chemotherapy, 2020 - Am Soc Microbiol
Currently, the expansion of the novel human respiratory coronavirus (known as SARS-CoV-
2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease …
2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease …
[HTML][HTML] Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence
B Russell, C Moss, G George, A Santaolalla… - …, 2020 - ncbi.nlm.nih.gov
Background Cancer and transplant patients with COVID-19 have a higher risk of developing
severe and even fatal respiratory diseases, especially as they may be treated with immune …
severe and even fatal respiratory diseases, especially as they may be treated with immune …
COVID-19: drug targets and potential treatments
C Gil, T Ginex, I Maestro, V Nozal… - Journal of medicinal …, 2020 - ACS Publications
Currently, humans are immersed in a pandemic caused by the emerging severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health …
respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health …
A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19
B Cao, Y Wang, D Wen, W Liu, J Wang… - New England journal …, 2020 - Mass Medical Soc
Background No therapeutics have yet been proven effective for the treatment of severe
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open …
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open …
A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19
E Davoudi-Monfared, H Rahmani… - Antimicrobial agents …, 2020 - Am Soc Microbiol
To the best of our knowledge, there is no published study on the use of interferon β-1a (IFN
β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and …
β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and …